.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has chosen Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 and also measured one more nine titles in the area as overweight. The assets banking company stated in a note that it remains to strongly believe “diabesity is actually set to end up being.